Cognition Therapeutics Shares Exciting Phase 2 Study Outcomes
- Improvements Across Measures of Behavior, Function, Cognition and Movement -
- Expediting Plans to Advance CT1812 into Late-Stage Trials -
- Full Results to be Presented at International Lewy Body Dementia Conference -
- Cognition Therapeutics and Dr. Galvin Will Host Conference Call to Review Data -
PURCHASE, N.Y. - Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focusing on developing therapeutics for neurodegenerative conditions, recently announced significant topline findings from its exploratory Phase 2 SHIMMER study. This study, which evaluated the effects of CT1812 on patients suffering from dementia with Lewy bodies (DLB), demonstrated promising therapeutic responses across various measures including behavior, function, cognition, and movement.
Dr. James E. Galvin, a principal investigator of the study and director at the Comprehensive Center for Brain Health at the University of Miami, emphasized the promising nature of these results. “The findings indicate that CT1812 could impact DLB patients positively across multiple dimensions of performance,” Dr. Galvin remarked. He expressed excitement for the next steps of the project and the potential benefits for patients and their families.
The SHIMMER study was meticulously designed as a signal-finding trial, enrolling 130 participants diagnosed with mild to moderate DLB. Over six months, these participants were randomly assigned to two dosing groups receiving either CT1812 or a placebo. Results revealed that the study successfully met its primary endpoint, demonstrating safety and tolerability. Notably, patients administered CT1812 exhibited noticeable improvements in behavioral indicators and a substantial reduction in neuropsychiatric inventory, with an impressive 82% decrease in symptoms such as anxiety and delusions. Additionally, caregiver distress was significantly alleviated, marking a positive shift in the quality of life for both patients and their caregivers.
Among cognitive measures, participants demonstrated a 91% decline in fluctuations in attention compared to those receiving a placebo. These groundbreaking findings are set to be elaborated upon at the International Lewy Body Dementia Conference in the near future.
Dr. Anthony Caggiano, Cognition’s chief medical officer, noted that these topline results surpassed expectations, highlighting CT1812's promise across various neurodegenerative disorders. The detailed analysis will continue as further data becomes available, preparing for presentations at upcoming medical venues and discussions with regulatory bodies about the future path for CT1812.
Given the results from both the SHIMMER and SHINE studies, there is growing confidence in CT1812's potential clinical efficacy in treating DLB and Alzheimer’s disease. Lisa Ricciardi, the president and CEO of Cognition, conveyed a sense of urgency in progressing with these late-stage clinical trials, emphasizing the desperate need for effective treatments in managing the complexities of neurodegenerative diseases.
Investor Webinar Information
Cognition Therapeutics will provide a comprehensive review of the findings during a conference call webcast. This session, scheduled for a morning time slot, will feature Dr. Galvin among others, with a live Q&A to follow the main presentations. Access to this event will be available through the Investor Relations section of the Cognition webpage.
Understanding Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies is recognized as the second most prevalent cause of dementia, impacting approximately 1.4 million Americans. It is characterized by the significant buildup of ?-synuclein protein in nerve cells related to cognitive decline, autonomic dysregulation, and various movement disorders. Initial symptoms can vary greatly, presenting as hallucinations, cognitive fluctuations, and disrupted REM sleep patterns. Currently, treatments often aim to alleviate symptoms rather than modify the disease course, highlighting a significant unmet need for accessible, effective therapies.
The Significance of the SHIMMER Study
The SHIMMER study, a meticulously structured Phase 2 clinical trial, evaluated 130 adult participants diagnosed with mild to moderate DLB. This double-blind, placebo-controlled study utilized diverse assessment tools, including the Neuropsychiatric Inventory and other cognitive performance measures. Such an extensive approach ensures a comprehensive understanding of CT1812's therapeutic potential across various neurodegenerative conditions.
About CT1812
CT1812 is a promising investigational oral small molecule designed to penetrate the blood-brain barrier and engage selectively with the sigma-2 receptor complex, critical for regulating cellular processes often disrupted in neurodegenerative conditions. Ongoing clinical programs also examine CT1812's effectiveness in treating Alzheimer's disease and other related conditions, reflecting Cognition’s commitment to addressing significant health challenges.
Contact Information
Cognition Therapeutics, Inc. can be reached via email at info@cogrx.com for general inquiries. For media inquiries, Casey McDonald at Tiberend Strategic Advisors can be contacted at cmcdonald@tiberend.com, while investor relations can connect through Mike Moyer at LifeSci Advisors at mmoyer@lifesciadvisors.com.
Frequently Asked Questions
What is the significance of the SHIMMER study results?
The SHIMMER study results indicate CT1812's potential to improve various health measures for DLB patients, suggesting strong therapeutic efficacy.
What is CT1812 aimed at treating?
CT1812 is developed to treat dementia with Lewy bodies (DLB) and potentially other neurodegenerative diseases, including Alzheimer’s.
Who conducted the SHIMMER study?
The SHIMMER study was conducted by Cognition Therapeutics, with a principal investigator, Dr. James E. Galvin, leading the research efforts.
When will more detailed data be available?
Detailed data from the SHIMMER study will be presented at the International Lewy Body Dementia Conference in the near future.
How can I learn more about Cognition Therapeutics?
More information about Cognition Therapeutics and ongoing research can be found on their official website.
